Anti-Human VEGFR2/KDR/Flk-1 Recombinant Nanobody (SAA1230) (HW338023)

Name: Anti-Human VEGFR2/KDR/Flk-1 Recombinant Nanobody (SAA1230)
Brand: abinScience
SKU: HW338023
Price: 126 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HW338023

Description

Anti-Human CD309/KDR/VEGFR-2 Nanobody (SAA1230) [SAA1230] (HW338023) is a alpaca monoclonal antibody detecting VEGFR-2 in ELISA, FCM, SPR. Suitable for Human.

Highlights

●Multi-Application — Validated across multiple applications.
●Flow Cytometry — Validated for flow cytometry applications.

Species reactivity

Human

Applications

ELISA, FCM, SPR

Host species

Alpaca

Clonality

Monoclonal

Isotype

VHH-8His-Cys-tag

Clone ID

SAA1230

Target

CD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2

Endotoxin level

< 10 EU/mg

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P35968

Form

Liquid

Storage buffer

0.01M PBS pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human CD309/KDR/VEGFR-2 Nanobody (SAA1230)
Bioactivity

Detects recombinant CD309 (Catalog No: HW338011) in indirect ELISA.
Immunofluorescence

Immunofluorescence staining of Hepg2 with Alpaca monoclonal antibody (20ug/ml, overnight at 4°C), followed by Alexa Fluor-488-conjugated secondary antibody (6.5ug/ml, 50minutes at room temperature). The target protein was detected in the Cytoplasm ，Nucleus ，Cell membrane,Secreted .